Development and application of individualized TIPS portal vein puncture 3D Printing guide device

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037408

Enrollment

Unknown

Registered

2020-08-28

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Portal hypertension

Interventions

Experimental group:3D printing guided TIPS

Control group:Conventional tips

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years old, understand the study process and agree to participate, sign the relevant informed consent; 2. Hepatic portal hypertensive gastrointestinal bleeding due to cirrhosis diagnosed by imaging and laboratory examination by any cause; 3. Gastroesophageal endoscopy confirmed secondary to esophageal cirrhosis with varicose veins bleeding; 4. Refractory ascites (the diagnostic criteria refer to the 2017 Chinese Society of Liver Disease: Guidelines for the diagnosis and treatment of cirrhosis ascites and related complications); 5. Liver function child-pugh score A or B (score 7); 6. liver function Child B-pugh score B with a large amount of ascites and Child-Pugh score C can be performed liver transplantation surgery, or with indications for liver transplantation acute bleeding or recurrent bleeding, TIPS treatment.

Exclusion criteria

Exclusion criteria: 1. Portal vein thrombosis; 2. Cavernous degeneration of portal vein; 3. Diffuse malignant tumor of liver, portal venous thrombus; 4. Contraindications for TIPS surgery, such as obvious liver damage (TBIL5mg/dL), congestive heart failure or severe valvular cardiac insufficiency, severe pulmonary hypertension, severe renal insufficiency, rapid progression of liver failure; 5. There are severe chronic concomitant diseases, embolus events, mental illness, severe infection, combined syphilis or HIV; 6. Pregnancy, contrast agent allergy or other contraindications of angiography.

Design outcomes

Primary

Measure	Time frame
Times of portal vein puncture;	—

Secondary

Measure	Time frame
Stent patency rate;	—

Countries

China

Contacts

Public ContactNaijian Ge

The Third Affiliated Hospital of Naval Military Medical University

gelarge@163.com+86 13917466607

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026